Organised by the FIP Social and Administrative Pharmacy Section in collaboration with the FIP Community Pharmacy Section, the FIP Hospital Pharmacy Section and the FIP Industrial Pharmacy Section
After a medicine has obtained a marketing authorisation, a great body of research on optimising health outcomes is conducted. Such research includes real-world evidence studies by marketing authorisation holders (pharmaceutical industry), for example, health economic evaluations, post-authorisation safety, and comparative effectiveness studies. In addition, outcomes of therapies, pharmaceutical services, and quality and safety in healthcare are studied by entities other than the pharmaceutical industry, for example, by health authorities, insurers, healthcare organisations (such as hospitals), often in collaboration with academia. Research after marketing authorisation may be conducted to meet regulatory demands, to inform decisions on reimbursement for the medicine, to optimise patient outcomes and to improve the delivery of high-quality and value healthcare across settings.
Even though research after marketing authorisation in different settings shares the same goal of optimising patient outcomes and improving the quality and value of healthcare, the real-world evidence studies by pharmaceutical industry and by other entities are commonly conducted separately, with little collaboration. This session will provide an overview of the variety of research being conducted after marketing authorisation, and discuss new collaborative research models with the goal of further optimising patient outcomes as well as improving the quality and value of healthcare.
14:30 – 14:35 Introduction by the chairs
17:20 – 17:30 Conclusion by the chairs
At the end of this session, participants will be able to:
Type of session: Knowledge-based